Anyone monitoring Ranbaxy’s shareholding pattern in December 2013 would have noticed a new entrant by the name of Silverstreet Developers with a 1.41% stake in the Daiichi Sankyo subsidiary. By March, the same entity had further raised its stake to 1.64%. Though not a significant jump, discerning investors would have known that something was up.
Editor's Pick
Most Popular
Summer wine and salad
Kishore Singh - January 19, 2015
A double topping for growth
Meghna Maiti - January 15, 2015
Scriptures for success
Kripa Mahalingam - January 27, 2015
Where's the party tonight?
Aditi Saxena - January 27, 2015
The million-dollar question: Is investing a game of luck or skill?
Shankar Sharma - May 04, 2021